Nicox Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

NicoxDie Umsatzerlöse des Unternehmens werden voraussichtlich um 2.1% pro Jahr zurückgehen, während die jährlichen Gewinne voraussichtlich um 3.7% pro Jahr wachsen werden. Der Gewinn pro Aktie wird voraussichtlich um 20.8% pro Jahr wachsen.

Wichtige Informationen

3.7%

Wachstumsrate der Gewinne

20.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	37.4%
Wachstumsrate der Einnahmen	-2.1%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	15 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

LSE:0RCQ - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	3	-16	N/A	N/A	1
12/31/2024	6	-14	N/A	N/A	1
12/31/2023	4	-15	N/A	N/A	1
6/30/2023	4	-17	-21	-21	N/A
3/31/2023	3	-23	-22	-22	N/A
12/31/2022	3	-28	-23	-23	N/A
9/30/2022	5	-38	-21	-21	N/A
6/30/2022	7	-49	-19	-19	N/A
3/31/2022	7	-46	-19	-19	N/A
12/31/2021	7	-44	-18	-18	N/A
9/30/2021	10	-29	-20	-20	N/A
6/30/2021	12	-15	-21	-22	N/A
3/31/2021	12	-17	-13	-13	N/A
12/31/2020	13	-18	-5	-5	N/A
9/30/2020	8	-25	N/A	N/A	N/A
6/30/2020	4	-33	2	2	N/A
3/31/2020	5	-26	-7	-7	N/A
12/31/2019	7	-19	-16	-16	N/A
9/30/2019	8	-15	N/A	N/A	N/A
6/30/2019	9	-11	-23	-22	N/A
3/31/2019	7	-15	-21	-21	N/A
12/31/2018	4	-18	-19	-19	N/A
6/30/2018	3	-4	-12	-12	N/A
3/31/2018	2	-6	-12	-12	N/A
12/31/2017	2	-8	-12	-12	N/A
6/30/2017	0	-6	-19	-19	N/A
3/31/2017	0	-6	N/A	-22	N/A
12/31/2016	0	-7	N/A	-26	N/A
9/30/2016	0	-15	N/A	-25	N/A
6/30/2016	0	-22	N/A	-24	N/A
3/31/2016	0	-21	N/A	-23	N/A
12/31/2015	0	-20	N/A	-22	N/A
6/30/2015	4	-21	N/A	-30	N/A
3/31/2015	5	-22	N/A	-32	N/A
12/31/2014	6	-22	N/A	-33	N/A
6/30/2014	2	-13	N/A	-26	N/A
3/31/2014	1	-13	N/A	N/A	N/A
12/31/2013	0	-11	N/A	-19	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 0RCQ wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: 0RCQ wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: 0RCQ wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: 0RCQDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-2.1% pro Jahr).

Hohe Wachstumseinnahmen: 0RCQDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-2.1% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 0RCQ in 3 Jahren voraussichtlich hoch sein wird

Nicox Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

No longer forecast to breakeven

Recent updates

New major risk - Financial data availability

Nicox SA Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470

No longer forecast to breakeven

Nicox S.A. Announces Board Changes

New minor risk - Shareholder dilution

Nicox S.A., Annual General Meeting, Jun 28, 2024

High number of new and inexperienced directors

New minor risk - Financial data availability

Nicox SA Receives Confirmation of 5-Year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA

Nicox's Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 Compared to Lumigan

First half 2023 earnings released: €0.13 loss per share (vs €0.39 loss in 1H 2022)

New major risk - Revenue and earnings growth

Nicox S.A. to Report Q2, 2023 Results on Jul 19, 2023

Full year 2022 earnings released

Nicox S.A., Annual General Meeting, Feb 28, 2023

Nicox S.A., Annual General Meeting, Feb 14, 2023

Nicox S.A. Outlines Future Development and Partnering Plans for Ncx 470 in Glaucoma

Nicox S.A. Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucoma Trial for NCX 470

Nicox S.A. Announces Last Patients Complete Final Visit in Ncx 470 Phase 3 Mont Blanc Glaucoma Trial

First half 2022 earnings released: EPS: €0 (vs €0.32 loss in 1H 2021)

Nicox Appoints Jean-Francois Labbé as Chairman of the Board of Directors

Nicox Announces Publication of NCX 470 Results Demonstrating Improvements to Ocular Hemodynamics and Retinal Cell Physiology

Nicox S.A., Annual General Meeting, Jun 28, 2022

Nicox S.A. Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial to November 2022

Nicox S.A. Announces Executive Changes

Nicox S.A., Annual General Meeting, Jun 14, 2022

Full year 2021 earnings released: €1.17 loss per share (vs €0.54 loss in FY 2020)

Nicox’s NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucoma

Nicox’s Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE® in China

Nicox Announces VYZULTA Now Commercialized in 7 Territories and Approved in Further 9 Countries

Nicox S.A. Announces Chinese National Intellectual Property Administration Grant A Formulation Patent for NCX 470

Nicox’s Positive FDA Meeting Shows Clear Path for NCX 4251 in Dry Eye

Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 Trial in Glaucoma

Nicox S.A. Announces Positive Post Hoc Results from Its Mississippi Phase 2B Clinical Trial Suggesting That Once-Daily Dosed NCX 4251

Nicox SA Reports New Data on NCX 470 in Nonclinical Model of Retinal Cell Damage Induced by Endothelin-1

First half 2021 earnings released

Nicox S.A. Announces Results from the NCX 4251 Phase 2B Mississippi Blepharitis Trial

High number of new and inexperienced directors

Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2B Blepharitis Trial

Nicox SA Presented Results from the Dolomites Phase 2 Clinical Trial Showing That NCX 470

Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates

Nicox SA to Present NCX 470 Dolomites Phase 2 Results in Glaucoma Patients at the World Glaucoma E-Congress 2021

Nicox's Completes Pre-Defined Enrollment of NCX 4251 Mississippi Phase 2b Blepharitis Trial

Nicox’s Licensee Bausch + Lomb Launches VYZULTA® (Latanoprostene Bunod Ophthalmic Solution), 0.024% in Taiwan and Receives Approval in Qatar

U.S. Patent Office Issues Notice of Allowance for Nicox’s Latanoprostene Bunod in Normal Tension Glaucoma

Nicox S.A., Annual General Meeting, Apr 14, 2021

Full year 2020 earnings released

Nicox S.A. to Report Fiscal Year 2020 Results on Mar 01, 2021

Nicox Announces the Publication in Leading Scientific Journal of Pre-Clinical Efficacy Results on a New Class of Non-PGA NO-donating IOP-Lowering Compounds

Nicox S.A. Licensee Bausch + Lomb Secures Approval of VYZULTA in Colombia

Nicox Initiates Phase 2b Trial of NCX 4251, a Potential First-in-Class Treatment for Blepharitis

Nicox’s Partner Fera Pharmaceuticals to Investigate Naproxcinod as Potential Covid-19 Adjuvant Treatment

Nicox S.A. has completed a Follow-on Equity Offering in the amount of €15.000651 million.

Nicox SA Initiates Second Phase 3 Trial of NCX 470 in Glaucoma

Nicox Announces Plans for NCX 4251 Phase 2 Trial in Blepharitis

Nicox Selects 0.1% NCX 470 Dose in Adaptive Stage of Mont Blanc Phase 3 Glaucoma Trial

Nicox SA Nicox Announces Senior Management Change

Nicox S.A. to Report First Half, 2020 Results on Sep 10, 2020

GHO Capital Fund I LP managed by GHO Capital Partners LLP entered into an agreement to acquire remaining unknown minority stake in VISUfarma B.V from Nicox S.A. (ENXTPA:COX) for €5 million

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken